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Introduction: Increasing short term safety concerns have been reported concerning the use of 
inotropes and/or vasopressors in the initial management of acute heart failure (AHF). However, 
data on long-term safety of these agents is scarce. We therefore sought to assess safety, especially 
long term mortality, of intravenous inotropes and/or vasopressors in AHF by a post-hoc analysis of 
a large AHF registry. 
 
Methods: The European Society of Cardiology Heart Failure Long – Term Registry (ESC-HF-LT) 
was a multicenter prospective observational registry conducted in 21 countries between 2011 and 
2013. Median follow-up duration was 381 [363; 457] days. For present analysis we selected 
patients (pts) with unscheduled hospitalizations for AHF, for whom intravenous (IV) therapy was 
needed (n=6900), including 833 (12%) pts who received one or more inotropes and/or 
vasopressors. A further analysis of 1212 pts was derived using propensity score matching (606 pts 
in each treatment group) in which 35 baseline variables were balanced as assessed by standardized 
mean differences. Primary endpoint was long-term all-cause mortality. Secondary endpoints were 
in-hospital mortality, all-cause post-discharge mortality and post-discharge rehospitalization. 
 
Results: Long-term all-cause mortality was greater in pts receiving IV inotrope and/or vasopressor 
compared to those who did not, both in the whole (43.7 % vs. 23.2 %) and the matched cohorts 
(39.8 % vs. 29.4 %). Adjusted hazard ratio (HR) for the association between the use of IV inotrope 
and/or vasopressor and long-term all-cause mortality was 1.720 [1.498 – 1.975] in the whole 
cohort and 1.434 [1.128-1.823] in the matched cohort. Adjusted HR for associations between the 
use of IV inotrope and/or vasopressor and in-hospital mortality were 3.138 [2.432-4.048] in the 
whole and 1.873 [1.151 – 3.048) in the matched cohorts. Adjusted HR for long-term all-cause 
mortality in patients discharged alive were 1.249 [1.059-1.474] in the whole and 1.078 [0.769-
1.512] in the matched cohorts. No association was found between the use of IV inotropeand/or 
vasopressor and post-discharge rehospitalization, neither in the whole nor in the matched cohorts 
(HR 1.101 [0.924-1.311] and 1.117 [0.788-1.582] respectively). 
 
Conclusions: The use of inotropes and/ or vasopressors in AHF was associated with increased 
long-term risk of all-cause death. 
  
 
 
 
 
